4 Similarly, in tirzepatides SURMOUNT-1 study, 9-15% lost less than 5% and 16-31% loss less than 10% (dose-dependent)
No offense
NS versus the corresponding control with Bonferronis post hoc test
The 10 Stages Clinical Safety Screens Performed MTC & MEN2 contraindications screened three separate times across the flow Dedicated eating disorder screen Anorexia Nervosa, Bulimia Nervosa, purging, laxative use Mental health hospitalization depression, bipolar disorder, schizophrenia history Suicidal ideation dedicated standalone screen Organ function kidneys, liver, and cardiac function each get their own screen Comorbidity multi-select diabetes, hypertension, heart disease, thyroid, asthma/COPD, anxiety, depression, HIV/AIDS, and more Pancreatitis & thyroid cancer individual confirmation screens in addition to multi-select Comprehensive family history FDA-specific (MEN2/MTC) plus cardiovascular, metabolic, and Long QT syndrome Injection safety prior injection experience, past injection problems, and comfort with self-administration three separate screens Reproductive status 8-option screen including pregnancy intent and breastfeeding AgelessRx does not use a validated PHQ-2 or PHQ-9 depression screening tool mental health is addressed through a hospitalization history question rather than a clinical screen
